IGC Pharma CEO swaps $601K debt for shares
IGC Pharma CEO Mukunda Ram acquired 2,226,475 shares of common stock in a private placement by cancelling $601,148 of debt the company owed him.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
IGC Pharma CEO Mukunda Ram acquired 2,226,475 shares of common stock in a private placement by cancelling $601,148 of debt the company owed him. The shares were issued at $0.27 each as restricted securities under Rule 144, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The deal was approved in advance by disinterested directors and the Audit Committee for Rule 16b-3 purposes, and Ram now directly holds 6,875,563 shares of IGC Pharma common stock.
Insider Trade Summary
Grant/Award: 2,226,475 shares
Grant/Award
1 txn
Insider
Mukunda Ram
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,226,475 | $0.27 | $601K |
Holdings After Transaction:
Common Stock — 6,875,563 shares (Direct)
Footnotes (1)
- F1. Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $601,148 of outstanding indebtedness owed by the Issuer to the Reporting Person. The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3.
Key Figures
Shares acquired: 2,226,475 shares
Issue price: $0.27 per share
Debt cancelled: $601,148
+1 more
4 metrics
Shares acquired
2,226,475 shares
Common stock received in private placement on 2026-06-30
Issue price
$0.27 per share
Price for newly issued common stock
Debt cancelled
$601,148
Outstanding indebtedness exchanged for shares
Post-transaction holdings
6,875,563 shares
CEO’s direct common stock position after transaction
Key Terms
private placement, restricted securities, Rule 144, Section 4(a)(2) of the Securities Act of 1933, +1 more
5 terms
private placement financial
"Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
restricted securities regulatory
"The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144"
Restricted securities are shares or other investment instruments that come with legal or contractual limits on when and how they can be sold, like stock given to founders or bought in a private offering. Think of them as assets in a locked box that can’t be freely traded until certain conditions — such as a waiting period, company registration, or specific approvals — are met. For investors this matters because restricted securities are less liquid and can affect timing, price, and perceived value when they eventually enter the market.
Rule 144 regulatory
"are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Section 4(a)(2) of the Securities Act of 1933 regulatory
"transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933"
Rule 16b-3 regulatory
"Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did IGC (IGC) report for CEO Mukunda Ram?
IGC Pharma reported that CEO Mukunda Ram acquired 2,226,475 common shares. The shares were received in exchange for cancelling company debt, rather than through an open-market purchase or sale, and increased his direct holdings to 6,875,563 shares.
What amount of IGC Pharma debt was cancelled in this insider transaction?
The transaction cancelled $601,148 of outstanding indebtedness that IGC Pharma owed to CEO Mukunda Ram. In return, he received 2,226,475 restricted common shares, effectively converting that debt claim into equity at a price of $0.27 per share.
Who approved the IGC Pharma debt-for-equity transaction with the CEO?
The transaction was approved in advance by IGC Pharma’s disinterested directors and the Audit Committee. CEO Mukunda Ram was recused from this approval process, and the structure was intended to satisfy Rule 16b-3 requirements for insider transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
